Cyclopharm Limited (ASX:CYC – Get Rating) insider Kevin Barrow purchased 10,000 shares of Cyclopharm stock in a transaction on Friday, December 2nd. The shares were acquired at an average cost of A$1.38 ($0.93) per share, for a total transaction of A$13,800.00 ($9,261.74).
Cyclopharm Stock Performance
The company has a debt-to-equity ratio of 10.92, a quick ratio of 4.68 and a current ratio of 5.53.
About Cyclopharm
Read More
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for Cyclopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclopharm and related companies with MarketBeat.com's FREE daily email newsletter.